Storia in 2 fonti

Pfizer drug acquired in Seagen deal disappoints in lung cancer study

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mese fa

Pfizer drug acquired in Seagen deal disappoints in lung cancer study

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.

originale

endpoints.news1 mese fa

Pfizer's $43B Seagen bet sours further as ADC fails in late-stage lung cancer trial

Pfizer's sigvotatug vedotin fails Phase 3 lung cancer trial, the third Seagen-acquired ADC to disappoint in roughly a year.

Leggi questa versione → originale

Timeline cronologica

martedì 23 giugno 2026·biopharmadive.com
Pfizer drug acquired in Seagen deal disappoints in lung cancer study
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.
martedì 23 giugno 2026·endpoints.news
Pfizer's $43B Seagen bet sours further as ADC fails in late-stage lung cancer trial
Pfizer's sigvotatug vedotin fails Phase 3 lung cancer trial, the third Seagen-acquired ADC to disappoint in roughly a year.